Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.

Ozempic and similar products cut opioid and alcohol abuse by up to half, according to research that adds to evidence of the hugely popular blockbuster drugs’ broad potential beyond tackling obesity and diabetes.

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Weight loss medications such as Ozempic may be able to cut drug and alcohol abuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found that people who take Ozempic or similar drugs — those used for weight loss or treating type 2 diabetes — were 40

Weight loss drugs such as Ozempic, Wegovy and Mounjaro may lower opioid overdose and alcohol intoxication rates among opioid addicts and alcoholics, respectively, according to a new study by three Loyola University Chicago researchers.